Laboratory of Nanomedicine, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, 751023, Odisha, India.
Regional Center for Biotechnology, Faridabad, Haryana, 121001, India.
Curr Med Chem. 2023;30(29):3335-3355. doi: 10.2174/0929867329666220922111336.
Cancer remains a major worldwide health challenge. Current studies emphasize the tumor microenvironment that plays a vital role in tumor proliferation, invasion, metastasis, and drug resistance. The tumor microenvironment (TME) supports the cancer cell to evade conventional treatment such as surgery, radiotherapy, and chemotherapy. Moreover, the components of tumor microenvironments have a major contribution towards developing therapy resistance in solid tumors. Therefore, targeting the tumor microenvironment can be a novel approach for achieving advancement in cancer nanomedicine. The recent progress in understanding TME and developing TME-responsive nanoparticles offers a great advantage in treating cancer drug resistance. These nanoparticles are developed in response to TME stimuli such as low pH, redox, and hypoxia improve nanomedicine's pharmacokinetic and therapeutic efficacy. This review discusses the various components of the tumor microenvironment responsible for drug resistance and nanomedicine's role in overcoming it.
癌症仍然是一个全球性的主要健康挑战。目前的研究强调肿瘤微环境在肿瘤增殖、侵袭、转移和耐药性方面起着至关重要的作用。肿瘤微环境（TME）支持癌细胞逃避手术、放疗和化疗等常规治疗。此外，肿瘤微环境的组成成分对实体瘤中治疗耐药性的发展有重大贡献。因此，针对肿瘤微环境可能是癌症纳米医学取得进展的一种新方法。对 TME 的理解和开发 TME 响应性纳米颗粒的最新进展为治疗癌症耐药性提供了很大的优势。这些纳米颗粒是针对 TME 刺激（如低 pH 值、氧化还原和缺氧）而开发的，可改善纳米医学的药代动力学和治疗效果。本文综述了肿瘤微环境中导致耐药性的各种成分以及纳米医学在克服耐药性方面的作用。
